Mylan Pharmaceuticals Inc
PharmaPittsburgh, Pennsylvania, United States · Est. 1956 · 35,000 employees
Mylan is a global pharmaceutical company that develops, licenses, manufactures, markets and distributes a wide range of generic, branded-generic and specialty pharmaceuticals.
0
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
0
Indications↗
Distinct diseases across all programs
160
Clinical Trials↗
All sponsored trials (all statuses)
Activity
Key Events
Dec 22, 2025TrialInvestigating Ovulation Inhibition for Use as a Contraceptive
Jan 13, 2025TrialStudy to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
Dec 22, 2023TrialDose-finding Study of MR-130A-01 Contraceptive Transdermal Patch
Nov 23, 2020TrialExtension Study of MYL-1701P-3001 for Safety and Efficacy
Aug 23, 2018TrialComparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)
Jan 21, 2017TrialMYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC
Details
Company Info
Company Overview
—
Mkt Cap
$11.2B
Revenue
—
Cash
CEORajiv Malik
Founded1956
Employees35,000
HQPittsburgh, Pennsylvania, United States
Websitemylan.com
LinkedInCompany Page
Therapeutic Focus
Generic pharmaceuticalsSpecialty pharmaceuticalsBiosimilars
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)